Expand KPTI Menu
KPTI MENU

KPTI Latest Press Releases

-- August 13, 2026 --

Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission PRNewswire 7:30 AM

-- August 11, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI Globe Newswire 6:21 PM

-- August 10, 2026 --

Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026 PRNewswire 7:30 AM

-- August 6, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI PRNewswire 11:02 PM

-- August 4, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI Globe Newswire 4:51 PM

-- August 3, 2026 --

Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) PRNewswire 4:05 PM

-- July 30, 2026 --

Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway PRNewswire 4:06 PM
Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer PRNewswire 4:05 PM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI PRNewswire 10:01 AM

-- July 1, 2026 --

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PRNewswire 4:05 PM

-- June 3, 2026 --

Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026 PRNewswire 4:15 PM

-- June 2, 2026 --

Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026 PRNewswire 10:03 AM
Karyopharm to Present Results from Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis in Late-Breaking Oral Presentation at ASCO 2026 with Simultaneous Publication in the Journal of Clinical Oncology PRNewswire 9:00 AM

-- June 1, 2026 --

Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) PRNewswire 4:05 PM
Karyopharm to Host Investor Conference Call Featuring Expert Perspectives on the Phase 3 SENTRY Trial in Myelofibrosis Following 2026 ASCO Presentation PRNewswire 7:30 AM

-- May 28, 2026 --

Karyopharm to Participate at the 2026 Jefferies Global Healthcare Conference PRNewswire 7:30 AM

-- May 14, 2026 --

Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment PRNewswire 7:30 AM

-- May 12, 2026 --

Karyopharm to Participate at Upcoming Investor Conferences PRNewswire 7:30 AM

-- May 7, 2026 --

Karyopharm to Report First Quarter 2026 Financial Results on May 14, 2026 PRNewswire 7:30 AM

-- April 21, 2026 --

Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Selected for Late-Breaking Oral Presentation at ASCO 2026 Annual Meeting PRNewswire 10:33 AM

-- March 24, 2026 --

Karyopharm Announces $30 Million Private Placement with RA Capital PRNewswire 7:01 AM
Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction PRNewswire 7:00 AM
Market Data Delayed 15 Minutes